nach oben

Erschienen in:

02.11.2023 | Research

Qualitative MR features to identify non-enhancing tumors within glioblastoma’s T2-FLAIR hyperintense lesions

verfasst von: Shota Yamamoto, Yoshiko Okita, Hideyuki Arita, Takahiro Sanada, Mio Sakai, Atsuko Arisawa, Naoki Kagawa, Eku Shimosegawa, Katsuyuki Nakanishi, Manabu Kinoshita, Haruhiko Kishima

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify qualitative MRI features of non-(contrast)-enhancing tumor (nCET) in glioblastoma’s T2-FLAIR hyperintense lesion.

Methods

Thirty-three histologically confirmed glioblastoma patients whose T1-, T2- and contrast-enhanced T1-weighted MRI and ¹¹C-methionine positron emission tomography (Met-PET) were available were included in this study. Met-PET was utilized as a surrogate for tumor burden. Imaging features for identifying nCET were searched by qualitative examination of 156 targets. A new scoring system to identify nCET was established and validated by two independent observers.

Results

Three imaging features were found helpful for identifying nCET; “Bulky gray matter involvement”, “Around the rim of contrast-enhancement (Around-rim),” and “High-intensity on T1WI and low-intensity on T2WI (HighT1LowT2)” resulting in an nCET score = 2 × Bulky gray matter involvement – 2 × Around-rim + HighT1LowT2 + 2. The nCET score’s classification performances of two independent observers measured by AUC were 0.78 and 0.80, with sensitivities and specificities using a threshold of four being 0.443 and 0.771, and 0.916 and 0.768, respectively. The weighted kappa coefficient for the nCET score was 0.946.

Conclusion

The current investigation demonstrated that qualitative assessments of glioblastoma’s MRI might help identify nCET in T2/FLAIR high-intensity lesions. The novel nCET score is expected to aid in expanding treatment targets within the T2/FLAIR high-intensity lesions.

Graphical abstract

Nur mit Berechtigung zugänglich

Sanai N, Polley MY, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.jns10998CrossRefPubMed

Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977–988. https://doi.org/10.3171/2015.5.jns142087CrossRefPubMed

Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. https://doi.org/10.3171/jns.2001.95.2.0190CrossRefPubMed

Kinoshita M, Arita H, Okita Y et al (2016) Comparison of diffusion tensor imaging and 11 C-methionine positron emission tomography for reliable prediction of tumor cell density in gliomas. J Neurosurg 125:1136–1142. https://doi.org/10.3171/2015.11.jns151848CrossRefPubMed

Molinaro AM, Hervey-Jumper S, Morshed RA et al (2020) Association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. Jama Oncol 6:495–503. https://doi.org/10.1001/jamaoncol.2019.6143CrossRefPubMedPubMedCentral

Sengupta A, Agarwal S, Gupta PK et al (2018) On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images. Eur J Radiol 106:199–208. https://doi.org/10.1016/j.ejrad.2018.07.018CrossRefPubMed

Takahashi S, Takahashi M, Kinoshita M et al (2021) Fine-tuning approach for segmentation of gliomas in brain magnetic resonance images with a machine learning method to normalize image differences among facilities. Cancers 13:1415. https://doi.org/10.3390/cancers13061415CrossRefPubMedPubMedCentral

Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474PubMedPubMedCentral

Lasocki A, Gaillard F, Tacey M et al (2015) Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Méd Imaging Radiat Oncol 60:66–73. https://doi.org/10.1111/1754-9485.12421CrossRefPubMed

10.

Lasocki A, Gaillard F (2019) Non-contrast-enhancing tumor: a new frontier in glioblastoma research. Am J Neuroradiol 40:758–765. https://doi.org/10.3174/ajnr.a6025CrossRefPubMedPubMedCentral

11.

Kracht LW, Miletic H, Busch S et al (2004) Delineation of brain tumor extent with [11C]l-methionine positron emission tomography. Clin Cancer Res 10:7163–7170. https://doi.org/10.1158/1078-0432.ccr-04-0262CrossRefPubMed

12.

Okita Y, Kinoshita M, Goto T et al (2010) 11C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage 49:2977–2982. https://doi.org/10.1016/j.neuroimage.2009.11.024CrossRefPubMed

13.

Kinoshita M, Arita H, Goto T et al (2012) A novel PET index, 18F-FDG–11C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med 53:1701–1708. https://doi.org/10.2967/jnumed.112.104992CrossRefPubMed

14.

Verburg N, Hoefnagels FWA, Barkhof F et al (2017) Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: a meta-analysis. Am J Neuroradiol 38:1884–1891. https://doi.org/10.3174/ajnr.a5368CrossRefPubMedPubMedCentral

15.

Arita H, Kinoshita M, Kagawa N et al (2011) 11C-methionine uptake and intraoperative 5‐aminolevulinic acid‐induced fluorescence as separate index markers of cell density in glioma. Cancer 118:1619–1627. https://doi.org/10.1002/cncr.26445CrossRefPubMed

16.

Galldiks N, Ullrich R, Schroeter M et al (2010) Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol I 37:84–92. https://doi.org/10.1007/s00259-009-1219-5CrossRef

17.

Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of l -[methyl-11C] methionine—positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507. https://doi.org/10.3171/jns.2005.103.3.0498CrossRefPubMed

18.

Hatakeyama T, Kawai N, Nishiyama Y et al (2008) 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol I 35:2009–2017. https://doi.org/10.1007/s00259-008-0847-5CrossRef

19.

Čížek J, Herholz K, Vollmar S et al (2004) Fast and robust registration of PET and MR images of human brain. Neuroimage 22:434–442. https://doi.org/10.1016/j.neuroimage.2004.01.016CrossRefPubMed

20.

D’Alessio A, Proietti G, Sica G, Scicchitano BM (2019) Pathological and molecular features of glioblastoma and its peritumoral tissue. Cancers 11:469. https://doi.org/10.3390/cancers11040469CrossRefPubMedPubMedCentral

21.

de Leeuw CN, Vogelbaum MA (2018) Supratotal resection in glioma: a systematic review. Neuro-Oncol 21:179–188. https://doi.org/10.1093/neuonc/noy166CrossRefPubMedCentral

22.

Verburg N, Koopman T, Yaqub MM et al (2019) Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neurooncology 22:412–422. https://doi.org/10.1093/neuonc/noz180CrossRef

23.

Yan JL, Li C, van der Hoorn A et al (2020) A neural network approach to identify the peritumoral invasive areas in glioblastoma patients by using MR radiomics. Sci Rep 10:9748. https://doi.org/10.1038/s41598-020-66691-6CrossRefPubMedPubMedCentral

24.

Chang PD, Malone HR, Bowden SG et al (2017) A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. Am J Neuroradiol 38:890–898. https://doi.org/10.3174/ajnr.a5112CrossRefPubMedPubMedCentral

25.

Lasocki A, Gaillard F, Tacey M et al (2018) Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. J Clin Neurosci 47:168–173. https://doi.org/10.1016/j.jocn.2017.09.007CrossRefPubMed

26.

Muccio CF, Tarantino A, Esposito G, Cerase A (2011) Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions. J Neuro-Oncol 103:713–717. https://doi.org/10.1007/s11060-010-0454-8CrossRef

27.

Kinoshita M, Uchikoshi M, Tateishi S et al (2021) Magnetic resonance relaxometry for tumor cell density imaging for glioma: an exploratory study via 11C-methionine PET and its validation via stereotactic tissue sampling. Cancers 13:4067. https://doi.org/10.3390/cancers13164067CrossRefPubMedPubMedCentral

28.

Yamamoto S, Sanada T, Sakai M et al (2022) Prediction and visualization of non-enhancing tumor in glioblastoma via T1w/T2w-ratio map. Brain Sci 12:99. https://doi.org/10.3390/brainsci12010099CrossRefPubMedPubMedCentral

29.

Hirata T, Kinoshita M, Tamari K et al (2018) 11C-methionine-18F-FDG dual-PET-tracer–based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg 131:676–686. https://doi.org/10.3171/2018.4.jns1859CrossRef

Titel: Qualitative MR features to identify non-enhancing tumors within glioblastoma’s T2-FLAIR hyperintense lesions
verfasst von: Shota Yamamoto
Yoshiko Okita
Hideyuki Arita
Takahiro Sanada
Mio Sakai
Atsuko Arisawa
Naoki Kagawa
Eku Shimosegawa
Katsuyuki Nakanishi
Manabu Kinoshita
Haruhiko Kishima
Publikationsdatum: 02.11.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04454-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience

The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma

Enhanced sensitivity of electrocorticography during awake craniotomy using a novel circular grid electrode

Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose?

Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT